The initiating of ETI therapy, alongside more effective monitoring of the patient's disease progression, has led to an improvement in the overall condition, with fewer pulmonary exacerbations and a favorable trend in the weight curve, with no signs of modulator-induced liver injury.
← all excerpts
Difficulties in the management of an Askin tumor in a pediatric patient with cystic fibrosis: case report and literature review.
1
—
—